Event company

PharmaEssentia: Company’s Board of Directors Approved Non-Binding Terms Sheet for the Distribution and Licensing of Ropeginterferon alfa-2b in the Latin America Region







close

Provided by: PharmaEssentia Corp.

SEQ_NO

1

announcement date

2022/05/29

Announcement time

12:59:35

Matter

 The Company's Board of Directors Approved the Non-
Binding Term Sheet for the Distribution and Licensing of
Ropeginterferon alfa-2b in the Latin American Region

Date of events

2022/05/27

What item it responds to

paragraph 10

Statement

1.Date of occurrence of the event:2022/05/27
2.Counterparty to the contract or commitment:
An international pharmaceutical company.
3.Relationship with the Company:None.
4.Starting and ending dates (or rescission date) of the
contract or commitment:NA
5.Major content (not applicable where rescinded):
The Company's Board of Directors approved the Non-Binding Term Sheet for
the distribution and licensing of Ropeginterferon alfa-2b in the Latin
American region, and authorized the Chairperson to negotiate and to sign
the definitive agreement.
6.Restrictive covenants (not applicable where rescinded):
As indicated in the confidentiality agreement.
7.Commitment (not applicable where rescinded):
As indicated in the confidentiality agreement.
8.Any other important agreement (not applicable where rescinded):
As indicated in the confidentiality agreement.
9.Effect on company finances and business:
Further announcement will be made upon the signing of the definitive
agreement.
10.Concrete purpose/objective:
To expand Ropeginterferon alfa-2b's market in the Latin American region
through registration, marketing, sales, and distribution.
11.Any other matters that need to be specified:
It takes a considerable time and expenses to develop a new drug.
In addition, the success of such development cannot be guaranteed.
Therefore, the investors will bear investment risk and should carefully
consider investment decisions.

Disclaimer

PharmaEssentia Corporation published this content on May 29, 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unmodified, on May 30, 2022 11:48:15 AM UTC.

Public now 2022

All the news of PHARMAESSENTIA CORPORATION

2022 sales 5,060M
173M
173M
2022 net income -139M
-4.75M
-4.75M
Net cash 2022 4,920M
168M
168M
PER 2022 ratio -718x
2022 return
Capitalization 99,920M
3,411 million
3,411 million
EV / Sales 2022 18.8x
EV / Sales 2023 7.54x
# of employees 131
Floating 71.4%

Chart PHARMAESSENTIA CORPORATION


Duration :

Period :




PharmaEssentia Corporation Technical Analysis Chart |  MarketScreener

Technical Trends in Analysis PHARMAESSENTIA CORPORATION

Short term Middle term Long term
Tendencies Bullish Neutral Bullish



Evolution of the income statement

Sale

To buy

Medium consensus TO BUY
Number of analysts 3
Last closing price TWD352.00
Average target price TWD395.33
Average Spread / Target 12.3%